On Friday, Aquestive Therapeutics Inc (NASDAQ: AQST) was 13.88% up from the session before settling in for the closing price of $5.26. A 52-week range for AQST has been $2.12 – $6.00.
A company in the Healthcare sector has jumped its sales by 27.90% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -24.31%. With a float of $111.23 million, this company’s outstanding shares have now reached $120.97 million.
Aquestive Therapeutics Inc (AQST) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aquestive Therapeutics Inc stocks. The insider ownership of Aquestive Therapeutics Inc is 8.06%, while institutional ownership is 37.59%. The most recent insider transaction that took place on Sep 26 ’25, was worth 480,464. Before that another transaction happened on Sep 19 ’25, when Company’s President and CEO sold 400 for $6.00, making the entire transaction worth $2,400. This insider now owns 1,014,773 shares in total.
Aquestive Therapeutics Inc (AQST) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.11 earnings per share (EPS) during the time that was better than consensus figure (set at -0.12) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -24.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.68% during the next five years compared to 27.90% growth over the previous five years of trading.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
You can see what Aquestive Therapeutics Inc (AQST) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.18. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.69, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Let’s dig in a bit further. During the last 5-days, its volume was 5.34 million. That was better than the volume of 1.8 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 55.05%.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 89.79%, which indicates a significant increase from 73.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.33 in the past 14 days, which was higher than the 0.25 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.38, while its 200-day Moving Average is $3.42. However, in the short run, Aquestive Therapeutics Inc’s stock first resistance to watch stands at $6.34. Second resistance stands at $6.69. The third major resistance level sits at $6.96. If the price goes on to break the first support level at $5.73, it is likely to go to the next support level at $5.46. Assuming the price breaks the second support level, the third support level stands at $5.11.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
There are 99,724K outstanding shares of the company, which has a market capitalization of 724.63 million. As of now, sales total 57,560 K while income totals -44,140 K. Its latest quarter income was 10,000 K while its last quarter net income were -13,550 K.
